Skip to main content

POTENCIAL DE RECEPTORES DE ADENOSINA A2A/A3 O HETEROMEROS A2A/A3 MICROGLIALES COMO DIANAS DE NEUROPROTECCION EN ENFERMEDAD DE ALZHEIMER

RTI2018-094204-B-I00

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos I+D+i Retos de Investigación
Call year 2018
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre UNIVERSIDAD DE BARCELONA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

The Binding Mode to Orthosteric Sites and/or Exosites Underlies the Therapeutic Potential of Drugs Targeting Cannabinoid CB2 Receptors

  • Franco, Rafael
  • Morales, Paula
  • Navarro, Gemma
  • Jagerovic, Nadine
  • Reyes-Resina, Irene
The classical terms agonists and antagonists for G protein coupled receptors (GPCRs) have often become misleading. Even the biased agonism concept does not describe all the possibilities already demonstrated for GPCRs. The cannabinoid CB receptor (CBR) emerged as a promising target for a variety of diseases. Reasons for such huge potential are centered around the way drugs sit in the orthosteric and/or exosites of the receptor. On the one hand, a given drug in a specific CBR conformation leads to a signaling cascade that differs qualitatively and/or quantitatively from that triggered by another drug. On the other hand, a given drug may lead to different signaling outputs in two different tissues (or cell contexts) in which the conformation of the receptor is affected by allosteric effects derived from interactions with other proteins or with membrane lipids. This highlights the pharmacological complexity of this receptor and the need to further unravel the binding mode of CBR ligands in order to fine-tune signaling effects and therapeutic propositions., This work was partially supported by AARFD-17-503612 grant of the US Alzheimer’s Association and by grants SAF 2017-84117-R, RTI 2018-094204-B-I00, RTI 2018-095544-B-I00 and PID 2020-113430RB-I00 funded by Spanish MCIN/AEI/10.13039/501100011033 and, as appropriate, by “ERDF A way of making Europe”, by the “European Union” or by the “European Union Next Generation EU/PRTR”. PM is a postdoctoral fellow supported by the Juan de la Cierva Programme-MICIU (IJC 2019-042182-I). The research group of the University of Barcelona is considered of excellence (grup consolidat #2017 SGR 1497) by the Regional Catalonian Government, which does not provide any specific funding for reagents or for payment of services or Open Access fees, Peer reviewed